COAG Hemab Therapeutics Holdings, Inc.

CIK 0002114044 5 ready 8-Ks latest August 11, 2026, 7:11 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 0 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 5

Latest filing September 24, 2026, 4:03 PM ET

Top materiality 0.85

Event mix leadership ×2 · earnings ×2 · other_material ×1

Sentiment 3 pos · 0 neg · 2 neu

Executive change recent →

Recent 8-K filings for COAG

Highest-materiality recent filing

Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

May 4, 2026, 7:59 PM ET other material materiality 0.85 positive item 5.03 item 8.01 item 9.01 ◈ Governance Changes ×2

IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.
Gross proceeds of $346.7 million before underwriting discounts and estimated offering expenses.

Read filing →

August 11, 2026, 7:11 AM ET earnings materiality 0.80 positive item 2.02 item 9.01

Hemab Q2 net loss $24.2M; FDA clears sutacimig Phase 3 in Glanzmann thrombasthenia

Net loss $24.2M ($0.80/share) vs $12.2M ($12.91/share) YoY; cash $457.5M, runway into 2029.
May 21, 2026, 7:05 AM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig

Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.
May 4, 2026, 7:59 PM ET other material materiality 0.85 positive item 5.03 item 8.01 item 9.01 ◈ Governance Changes ×2

Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.

Executive changes

Appointed

Keli Walbert

Director

COAG · Hemab Therapeutics Holdings, Inc.

Effective: 2026-09-24
Filed: September 24, 2026, 4:03 PM ET

On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Hemab Therapeutics Holdings, Inc. (the “Company”), the Board elected Keli Walbert to serve as a member of the Board, effective immediately.

Departed

Laura Tadvalkar

Director

COAG · Hemab Therapeutics Holdings, Inc.

Effective: 2026-05-08
Filed: May 11, 2026, 4:01 PM ET

On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event leadership

3 positive 0 negative 2 neutral

source · COAG on sec.gov